TECHNIVIE Drug Patent Profile

When do Technivie patents expire, and when can generic versions of Technivie launch?

Technivie is a drug marketed by Abbvie and is included in one NDA. There are six patents protecting this drug.

This drug has three hundred and ninety-three patent family members in forty-six countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Technivie

Technivie was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 13, 2032. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TECHNIVIE

International Patents:	393
US Patents:	6
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Drug Prices:	Drug price information for TECHNIVIE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TECHNIVIE
DailyMed Link:	TECHNIVIE at DailyMed

See drug prices for TECHNIVIE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TECHNIVIE

NDA:

207931

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TECHNIVIE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 3
AbbVie	Phase 2

See all TECHNIVIE clinical trials

US Patents and Regulatory Information for TECHNIVIE

TECHNIVIE is protected by six US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No			Y	Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No			Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y

EU/EMA Drug Approvals for TECHNIVIE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH Co. KG	Viekirax	ombitasvir, paritaprevir, ritonavir	EMEA/H/C/003839Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.	Authorised	no	no	no	2015-01-14

International Patents for TECHNIVIE

When does loss-of-exclusivity occur for TECHNIVIE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

France

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TECHNIVIE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	225186
Austria	392895
Australia	6342096
Australia	722812
Canada	2224738	EMPLOI DE RITONAVIR (ABT-538) POUR AMELIORER LA PHARMACOCINETIQUE DE MEDICAMENTS METABOLISES PAR LE CYTOCHROME P450 DANS UNE METHODE DE TRAITEMENT DU SIDA (USE OF RITONAVIR (ABT-538) FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY CYTOCHROME P450 IN A METHOD OF TREATING AIDS)

Supplementary Protection Certificates for TECHNIVIE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2340029	CA 2015 00013	Denmark		PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150115
2368890	PA2015012	Lithuania		PRODUCT NAME: OMBITASVIRUM; REGISTRATION NO/DATE: EU/1/14/982 20150115
2368890	CA 2015 00015	Denmark		PRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150115
2368890	C02368890/01	Switzerland		FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS
2340029	PA2015011	Lithuania		PRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115

Last updated: July 3, 2026

Technivie Market Dynamics and Financial Trajectory (2014–Present)

Technivie (ombitasvir/paritaprevir/ritonavir; 12.5 mg/75 mg/50 mg) is a once-daily, fixed-dose, interferon-free direct-acting antiviral (DAA) for chronic hepatitis C virus (HCV) genotype 4 in adults with compensated liver disease. The commercial trajectory has been defined by (1) rapid DAA category adoption starting in 2014, (2) payer and guideline-driven product rationalization toward pan-genotypic regimens, and (3) price compression and shrinking treatable population windows as sofosbuvir-based and pan-genotypic competitors became dominant.

Bottom line: Technivie’s financial profile is consistent with a niche, genotype-restricted DAA that peaked early in the category rollout and then faced sustained demand erosion as broader-efficacy, shorter, and less complex competitors replaced genotype 4-only therapy in routine care.

---

What is Technivie and how is it positioned in the HCV DAA market?

Direct answer: Technivie is an oral, fixed-dose combination DAA regimen for HCV genotype 4 adults with compensated liver disease, using daily dosing over a finite treatment course (commonly 12 weeks in practice and labeling contexts for genotype 4 treatment strategies).

Regimen composition and payer-relevant attributes

Technivie combines:

• Ombitasvir (NS5A inhibitor)
• Paritaprevir (NS3/4A protease inhibitor)
• Ritonavir (pharmacokinetic booster)

Commercial implications:

• Genotype restriction reduced addressable market versus pan-genotypic DAAs.
• Dosing complexity and resistance considerations can matter under payer prior authorization, particularly once simpler regimens became available.
• Safety and drug-drug interaction management (ritonavir-based boosters) can increase administrative friction, affecting uptake.

How the genotype-4-only niche shaped market adoption

From a demand standpoint, Technivie’s uptake is constrained by the share of treated patients who are genotype 4 and by how often genotype is definitively assigned before therapy. As treatment pathways shifted toward pan-genotypic strategies, genotype-specific options lost relevance in many formularies.

---

When did Technivie launch and how fast did it capture the HCV genotype 4 segment?

Direct answer: Technivie entered the U.S. market after approval in 2015 (category rollout began earlier with other DAAs). Uptake likely peaked in the mid-to-late 2010s as genotype testing and DAA substitution accelerated.

Adoption curve typical for first-wave DAAs

HCV DAAs generally show:

• Early physician adoption once interferon-free regimens proved efficacy and tolerability.
• Rapid payer coverage expansion after early reimbursement learning.
• Subsequent category consolidation as second-generation and pan-genotypic regimens displaced earlier, narrower products.

For Technivie, this pattern is amplified by genotype restriction, meaning the addressable population expanded only insofar as genotype 4 prevalence and testing practices supported it.

---

What competitive drugs displaced Technivie and how did that affect revenue?

Direct answer: Pan-genotypic DAA regimens and other simplified genotype-based alternatives compressed Technivie’s addressable market and pricing leverage, causing revenue erosion after early uptake.

Key displacement dynamics in later DAA waves

The market moved from:

• Genotype-stratified DAAs to
• Pan-genotypic regimens (and regimens that minimize genotype-specific decisioning)

This shift reduced formulary value for genotype-restricted competitors like Technivie.

Price compression and net price pressure

As multiple DAAs covered similar clinical endpoints:

• Wholesale acquisition price (WAC) became less informative than net price and rebates.
• Payers increasingly enforced price concessions through contracting and “least-cost” strategy.

Financial trajectory implication: Technivie revenue typically trends down over time as competitors take share and as payers negotiate to equalize net pricing across equivalent cure outcomes.

---

What patent and exclusivity constraints shaped Technivie’s commercial life?

Direct answer: Technivie’s commercial lifespan is primarily governed by standard small-molecule patent terms and regulatory exclusivity mechanics for DAAs, plus the market shift toward alternative regimens that reduced payer willingness to maintain a differentiated genotype-only product.

Exclusivity vs. practical exclusivity

Even before the expiration of patents, commercial outcomes can weaken due to:

• Formulary steering to preferred regimens
• Contracting and step therapy
• Clinical guideline updates that reduce the need for genotype-restricted therapy

Orange Book status and litigation risk

Because the question focuses on market dynamics and financial trajectory and not on a legal invalidation analysis, the critical point for business planning is that competition from other DAAs is not dependent on patent expiration. It is driven by guideline and payer contracting cycles.

---

How did FDA regimen guidance and guideline updates influence Technivie demand?

Direct answer: As HCV practice guidelines increasingly favored simplified, pan-genotypic regimens, genotype 4-only products faced declining utilization even without direct generic substitution.

Operational drivers inside payers and provider systems

• Prior authorization forms and criteria can become less favorable for older regimens when pan-genotypic alternatives are preferred.
• Drug interaction burden can increase administrative load when regimens contain boosters like ritonavir.
• Treatment pathways moved toward “one regimen fits most” to reduce testing variability.

Financial impact: utilization declines can precede any generic entry timeline.

---

What generic or biosimilar entry risks exist for Technivie?

Direct answer: For small-molecule DAAs like Technivie, the principal generic pathway is through ANDA and Paragraph IV certifications. Commercial risk is usually dominated by:

• Timing of core process and composition-of-matter patent expirations (legal trigger)
• The speed with which payers switch preferred regimens (market trigger)
• The presence of authorized generics or contract-based alternatives (commercial trigger)

Business takeaway on entry risk

Even when legal exclusivity delays generic competition, utilization can still fall materially due to competitive substitution. In the DAA category, “market competition” frequently outpaces “generic competition” in its impact on revenue.

---

What is Technivie’s Orange Book status and what does it imply for competitor entry timing?

Direct answer: Orange Book analysis requires specific listing-level data (drug, active ingredients, dosage form, patent numbers, and expiration dates). Without those listing inputs, a precise status statement cannot be produced here.

---

How does Technivie compare with AbbVie’s other HCV assets and with rival DAA portfolios?

Direct answer: Technivie is narrower than pan-genotypic AbbVie and competitor options, so it is structurally more exposed to formulary displacement as treatment complexity declines.

Portfolio logic

AbbVie’s HCV franchise more broadly benefits when it can offer regimens that address multiple genotypes with similar efficacy and simplified prescribing. Genotype 4-only positioning typically creates:

• Higher sensitivity to guideline narrowing
• Greater reliance on genotype testing and disease staging eligibility
• Smaller durable formulary presence once pan-genotypic coverage becomes standard

---

What financial trajectory indicators matter most for Technivie (and what direction do they move)?

Direct answer: For DAAs like Technivie, revenue trajectory is typically driven by:

• Uptake during early DAA rollout
• Utilization decline as pan-genotypic regimens dominate
• Net price pressure from contracting and class competition
• Remaining sales tied to residual genotype 4 treated volume and line-of-therapy behavior

Directionally expected pattern

• 2015–2017: strong adoption tailwind in genotype-defined cohorts and DAA conversion programs.
• 2018–2021: revenue flattening then decline as pan-genotypic regimens consolidate prescriber and payer behavior.
• 2022–Present: continued erosion as HCV incidence and treated pools shift toward newer options; remaining sales are smaller, more contract-dependent, and limited by regimen preference.

---

What are the commercialization bottlenecks that can suppress Technivie utilization?

Direct answer: The most common utilization suppressors for genotype-specific, booster-containing regimens are administrative and formulary friction, not just clinical efficacy.

Payer and clinician friction points

• Drug-drug interaction complexity (ritonavir boosting increases the need for medication reconciliation)
• Prior authorization documentation burden (genotype confirmation and cirrhosis status requirements)
• Loss of formulary priority due to preferred contracting for pan-genotypic regimens
• Guideline alignment toward simplified regimens that reduce testing and sequencing

---

Key Takeaways

• Technivie’s market dynamics are dominated by DAA category evolution: rapid early adoption followed by sustained formulary displacement.
• The regimen’s genotype 4-only positioning structurally limits addressable demand versus pan-genotypic therapies.
• Revenue erosion is typically driven by payer contracting and guideline updates, often before any generic entry.
• Financial trajectory planning should treat Technivie as a niche DAA with declining utilization and net price pressure rather than as a long-duration monopoly asset.

---

FAQs

Which HCV genotypes does Technivie cover and how does that affect market size?

Technivie is for HCV genotype 4. That restriction limits the addressable treated population compared with pan-genotypic regimens, shrinking potential durable volume under broad formularies.

Does Technivie face faster demand loss from guideline changes than from generic competition?

In HCV DAAs, demand often declines due to guideline and formulary steering toward newer simplified regimens, which can reduce utilization even absent generic entry.

How do payer prior authorization requirements influence Technivie uptake?

Payers can require genotype confirmation and patient characteristics documentation. If pan-genotypic options are preferred, administrative burden and formulary constraints can reduce Technivie usage.

What competitors most directly substitute for Technivie in treated genotype 4 populations?

Substitution typically comes from pan-genotypic DAAs and other regimens that reduce genotype testing and prescribing complexity while maintaining high cure rates.

What commercial metrics best track Technivie decline in later years?

Monitor net sales trends, estimated treated volume in genotype 4 cohorts, and formulary placement changes (preferred vs non-preferred status) as contract dynamics tighten.

---

References

No source materials were provided in the prompt, and no verifiable, drug-specific Orange Book or financial statement citations can be generated from the information available here.